Research programme: liposomal cancer therapies - Xenetic Biosciences

Drug Profile

Research programme: liposomal cancer therapies - Xenetic Biosciences

Alternative Names: Liposomal paclitaxel - Xenetic/Serum Institute of India; LipoTaxen; Paclitaxel liposomal - Xenetic/Serum Institute of India

Latest Information Update: 07 Oct 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lipoxen Technologies
  • Developer Xenetic Biosciences
  • Class Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Immunosuppressants; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Sep 2011 Lipoxen is now called Xenetic Biosciences
  • 04 Aug 2011 Research programme: liposomal cancer therapies is no longer licensed to Serum Institutes of India
  • 14 Jan 2005 Preclinical trials in Cancer in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top